199108-79-7

Upstream product

• 23356-96-9 (S)-1-Pyrrolidin-2-yl-methanol 
• 199109-42-7 5-benzyloxy-2,4,6,7-tetramethylbenzofuran-3-methylchloride 

Downstream Products

• 224954-19-2 5-<4-phenylmethyl>-2-imino-4-thiazolidinone 
• 199109-13-2 4-benzaldehyde 
• 199109-33-6 4-aniline 
• 199109-11-0 4-benzaldehyde 
• 199108-91-3 N-(5-benzyloxy-2,4,6,7-tetramethylbenzofuran-3-ylmethyl)-(3R)-chloropiperidine 
• 199109-28-9 4-nitrobenzene 

Relevant academic research and scientific papers

NOVEL HETEROCYCLIC COMPOUNDS HAVING ANTIDIABETIC, HYPOLIPIDAEMIC, ANTIHYPERTENSIVE PROPERTIES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

The present invention relates to novel antidiabetic compounds, their tautomeric forms, their derivatives, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. This invention particularly relates to novel azolidinedione derivatives of general formula (I), and their pharmaceutically acceptable salts, pharmaceutically acceptable solvates and pharmaceutical compositions containing them.

Heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them

The present invention relates to novel antidiabetic compounds, their tautomeric forms, their derivatives, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. This invention particularly relates to novel azolidinedione derivatives of the general formula (I), and their pharmaceutically acceptable salts, pharmaceutically acceptable solvates and pharmaceutical compositions containing them. STR1

Novel antidiabetic and hypolipidemic agents. 3. Benzofuran-containing thiazolidinediones

Several thiazolidinedione derivatives having 5-hydroxy-2,3-dihydro- 2,2,4,6,7-pentamethylbenzofuran moieties and their 5-benzyloxy derivatives and 5-hydroxy-2,4,6,7-tetramethylbenzofuran moieties were synthesized and evaluated in db/db mice. Insertion of an N-Me group into the linker between thiazolidinedione and substituted benzofuran pharmacophores showed considerable improvement in their euglycemic activity. Further improvement has been observed when a pyrrolidine moiety is introduced in the structure to give 5-[4-[N-[3(R/S)-5-benzyloxy-2,3-dihydro-2,2,4,6,7-pentamethylbenzofuran- 3-ylmethyl]-(2S)-pyrrolidin-2-ylmethoxy]phenylene]thiazolidine-2,4-dione (21a). At a 100 mg/kg/day dose of the maleate salt, compound 21a reduced the plasma glucose and triglyceride to the level of lean littermate, i.e. 8 ± 1 mM, and is the most potent and efficacious compound reported in this series.